Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
0 k3 y W3 e% m6 B' R, T; \NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
, f$ P) ?6 N1 [! p+ Author Affiliations2 W5 a1 Y3 m5 f3 [
5 W( ^7 z1 c( W0 j) a+ x0 W1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
: o6 E( k( p, B5 o# T4 U; p! l2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
+ G' Z. F h7 W5 |( @3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
3 G$ X4 H5 {$ B: A& t4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
) x8 [( g; A2 K$ B Q9 e* s" q5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
/ n! @. Z/ M* b7 K5 l6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
( e5 r: j# C# u! D v% m7Kinki University School of Medicine, Osaka 589-8511, Japan
! }9 @2 a! ~% g) _8Izumi Municipal Hospital, Osaka 594-0071, Japan
0 {7 n0 h8 p: U2 N' p* _2 ~9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
3 ?( c. I9 [8 d9 a' iCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
+ G# M/ P! w8 x7 r2 K8 A+ dAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
6 s9 d7 G0 N1 Y8 {4 R' l) m, ]) d; |/ V$ E
|